Investigation of the relationship between ameloblastoma and salivary uric acid levels and microRNAs

Investigation of the relationship between ameloblastoma and salivary uric acid levels and microRNAs - Uric acid levels and miRNAs in patients with ameloblastoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000057717

Enrollment

100

Registered

2025-04-25

Start date

2024-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ameloblastoma

Interventions

Measuring salivary uric acid levels and miRNAs involved in cell proliferation in patients with ameloblastoma. Measuring salivary uric acid levels and miRNAs involved in cell proliferation in healthy s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient group (1) Patients who have been diagnosed with enamel epithelioma (postoperative and scheduled surgery patients) in Department of Oral and Maxillofacial Surgery, Fukuoka Dental College Hospital. (2) Patients who fully understand this research plan and can give informed consent by themselves or their family (parents and guardians of minors). (3) Age 16 years or older at the time of obtaining informed consent. Control group (1) Patients who visit the outpatient dental clinic of Fukuoka Dental College Hospital with the main complaint of seeking dental treatment and are diagnosed as having no history of systemic diseases including ameloblastoma. (2) Patients who fully understand this research plan and can give informed consent by themselves or their family members.

Exclusion criteria

Exclusion criteria: Patient group (1) Patients who could not obtain consent. (2) Patients who are under treatment for or have a history of malignancy including oral cancer. (3) Other patients whom the investigator judges to be inappropriate as research subjects. (4) When consent is withdrawn during the study. Control group (1) Patients who could not obtain consent. (2) Patients who are under treatment for or have a history of malignancy including oral cancer. (3) Other patients whom the investigator judged to be inappropriate as research subjects. (4) In case of withdrawal of consent during the course of the study.

Design outcomes

Primary

Measure	Time frame
Salivary uric acid levels	—

Secondary

Measure	Time frame
,miRNAs associated with cell proliferation	—

Countries

Japan

Contacts

Public ContactHiromitsu Morita

Fukuoka Dental College Section of Dentistry for the Disabled, Department of Oral Growth and Development

morita@fdcnet.ac.jp092-801-0425

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026